OBJECTIVE: To assess the initial experiment with percutaneous closure of interventricular septal defects (IVSD), especially perimembranous IVSD (PMIVSD) with the new Amplatzer prosthesis. METHODS: Eleven patients were submitted to the procedure. Six of them had perimembranous IVSD (PMIVSD) and five with muscular IVSD (MIVSD). Two showed repeated respiratory tract infections and had low ponderal gain. One of them showed a previous history of infectious endocarditis. The others were asymptomatic and were selected through transthoracic echocardiography (TTE). RESULTS: In MIVSD group (n=5), a patient had apical IVSD, two had medioseptal defects and two patients showed multiple defects. In this group, an interatrial septal defects (IASD) (Amplatzer Septal Occluder®) and five prostheses for MIVSD (Amplatzer VSD-MUSC Occluder®), and one patient received two devices. All implants were well-succeeded and went by without complications. In PMIVSD group (n=6), two patients had membranous septal aneurysms. In five, we identified two orifices with selective angiography. We used arterial canal Amplatzer prostheses (ACP) (Amplatzer Duct Occluder®) in 1 patient and specific prostheses for PMIVSD in the others (Amplatzer VSD-MEMB Occluder®). A perimembranous occluder migrated immediately after released, being removed from the descending aorta. Another patient showed total atrioventricular block (TAVB), which reversed after corticotherapy. CONCLUSION: The procedure is technically complex and must be performed only in specialized centers. Despite of that, it showed safe and efficient in the selected cases, and it can be provided as an alternative to traditional surgical treatment.
interventricular septal defects; percutaneous occlusion; congenital cardiopathy; Amplatzer
